<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39456193</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>A Structural Investigation of the Interaction between a GC-376-Based Peptidomimetic PROTAC and Its Precursor with the Viral Main Protease of Coxsackievirus B3.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1260</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom14101260</ELocationID><Abstract><AbstractText>The conservation of the main protease in viral genomes, combined with the absence of a homologous protease in humans, makes this enzyme family an ideal target for developing broad-spectrum antiviral drugs with minimized host toxicity. GC-376, a peptidomimetic 3CL protease inhibitor, has shown significant efficacy against coronaviruses. Recently, a GC-376-based PROTAC was developed to target and induce the proteasome-mediated degradation of the dimeric SARS-CoV-2 3CL<sup>Pro</sup> protein. Extending this approach, the current study investigates the application of the GC-376 PROTAC to the 3C<sup>Pro</sup> protease of enteroviruses, specifically characterizing its interaction with CVB3 3C<sup>Pro</sup> through X-ray crystallography, NMR (Nuclear Magnetic Resonance) and biochemical techniques. The crystal structure of CVB3 3C<sup>Pro</sup> bound to the GC-376 PROTAC precursor was obtained at 1.9 Å resolution. The crystallographic data show that there are some changes between the binding of CVB3 3C<sup>Pro</sup> and SARS-CoV-2 3CL<sup>Pro</sup>, but the overall similarity is strong (RMSD on C-alpha 0.3 Å). The most notable variation is the orientation of the benzyloxycarbonyl group of GC-376 with the S4 subsite of the proteases. NMR backbone assignment of CVB3 3C<sup>Pro</sup> bound and unbound to the GC-376 PROTAC precursor (80% and 97%, respectively) was obtained. This information complemented the investigation, by NMR, of the interaction of CVB3 3C<sup>Pro</sup> with the GC-376 PROTAC, and its precursor allows us to define that the GC-376 PROTAC binds to CVB3 3C<sup>Pro</sup> in a mode very similar to that of the precursor. The NMR relaxation data indicate that a quench of dynamics of a large part of the protein backbone involving the substrate-binding site and surrounding regions occurs upon GC-376 PROTAC precursor binding. This suggests that the substrate cavity, by sampling different backbone conformations in the absence of the substrate, is able to select the suitable one necessary to covalently bind the substrate, this being the latter reaction, which is the fundamental step required to functionally activate the enzymatic reaction. The inhibition activity assay showed inhibition potency in the micromolar range for GC-376 PROTAC and its precursor. Overall, we can conclude that the GC-376 PROTAC fits well within the binding sites of both proteases, demonstrating its potential as a broad-spectrum antiviral agent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Santis</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0002-8685-7648</Identifier><AffiliationInfo><Affiliation>Magnetic Resonance Center CERM, University of Florence, Via Luigi Sacconi 6, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grifagni</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Magnetic Resonance Center CERM, University of Florence, Via Luigi Sacconi 6, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orsetti</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Magnetic Resonance Center CERM, University of Florence, Via Luigi Sacconi 6, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenci</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-7408-2828</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosato</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6172-0368</Identifier><AffiliationInfo><Affiliation>Magnetic Resonance Center CERM, University of Florence, Via Luigi Sacconi 6, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Onofrio</LastName><ForeName>Mariapina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8699-0847</Identifier><AffiliationInfo><Affiliation>Department of Biotechnology, University of Verona, Strada le Grazie 15, 37134 Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trabocchi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1774-9301</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciofi-Baffoni</LastName><ForeName>Simone</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2376-3321</Identifier><AffiliationInfo><Affiliation>Magnetic Resonance Center CERM, University of Florence, Via Luigi Sacconi 6, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantini</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0526-6732</Identifier><AffiliationInfo><Affiliation>Magnetic Resonance Center CERM, University of Florence, Via Luigi Sacconi 6, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calderone</LastName><ForeName>Vito</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-7963-6241</Identifier><AffiliationInfo><Affiliation>Magnetic Resonance Center CERM, University of Florence, Via Luigi Sacconi 6, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, University of Florence, Via della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>B/2021/0212</GrantID><Agency>Intesa Sanpaolo</Agency><Country /></Grant><Grant><GrantID>B53D23015510006</GrantID><Agency>European Union - NextGenerationEU</Agency><Country /></Grant><Grant><GrantID>B83C22003920001</GrantID><Agency>THE-Tuscany Health Ecosystem-ECS00000017</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057786">Peptidomimetics</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="D000086782">Coronavirus 3C Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057786" MajorTopicYN="Y">Peptidomimetics</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086782" MajorTopicYN="N">Coronavirus 3C Proteases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3-chymotrypsin-like protease</Keyword><Keyword MajorTopicYN="N">Coxsackievirus B3</Keyword><Keyword MajorTopicYN="N">GC-376</Keyword><Keyword MajorTopicYN="N">PROTAC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">viral main protease</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39456193</ArticleId><ArticleId IdType="pmc">PMC11506516</ArticleId><ArticleId IdType="doi">10.3390/biom14101260</ArticleId><ArticleId IdType="pii">biom14101260</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Komander D., Rape M. The ubiquitin code. Annu. Rev. Biochem. 2012;81:203–229. doi: 10.1146/annurev-biochem-060310-170328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-060310-170328</ArticleId><ArticleId IdType="pubmed">22524316</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng N., Shabek N. Ubiquitin Ligases: Structure, Function, and Regulation. Annu. Rev. Biochem. 2017;86:129–157. doi: 10.1146/annurev-biochem-060815-014922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-060815-014922</ArticleId><ArticleId IdType="pubmed">28375744</ArticleId></ArticleIdList></Reference><Reference><Citation>Morreale F.E., Walden H. Types of Ubiquitin Ligases. Cell. 2016;165:248–248.e241. doi: 10.1016/j.cell.2016.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.03.003</ArticleId><ArticleId IdType="pubmed">27015313</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshaies R.J., Joazeiro C.A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 2009;78:399–434. doi: 10.1146/annurev.biochem.78.101807.093809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.78.101807.093809</ArticleId><ArticleId IdType="pubmed">19489725</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman B.A., Harper J.W. Ubiquitin-like protein activation by E1 enzymes: The apex for downstream signalling pathways. Nat. Rev. Mol. Cell Biol. 2009;10:319–331. doi: 10.1038/nrm2673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2673</ArticleId><ArticleId IdType="pmc">PMC2712597</ArticleId><ArticleId IdType="pubmed">19352404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y., Rape M. Building ubiquitin chains: E2 enzymes at work. Nat. Rev. Mol. Cell Biol. 2009;10:755–764. doi: 10.1038/nrm2780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2780</ArticleId><ArticleId IdType="pmc">PMC3107738</ArticleId><ArticleId IdType="pubmed">19851334</ArticleId></ArticleIdList></Reference><Reference><Citation>Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 2009;78:477–513. doi: 10.1146/annurev.biochem.78.081507.101607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.78.081507.101607</ArticleId><ArticleId IdType="pmc">PMC3431160</ArticleId><ArticleId IdType="pubmed">19489727</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Crews C.M. PROTACs: Past, present and future. Chem. Soc. Rev. 2022;51:5214–5236. doi: 10.1039/D2CS00193D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2CS00193D</ArticleId><ArticleId IdType="pmc">PMC10237031</ArticleId><ArticleId IdType="pubmed">35671157</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciulli A.H.O. PROTAC Degraders Mechanism, Recent Advances, and Future Challenges. In: Jones M.K.L.H., editor. Protein Homeostasis in Drug Discovery: A Chemical Biology Perspective. John Wiley &amp; Sons, Inc.; Hoboken, NJ, USA: 2022. pp. 317–356.</Citation></Reference><Reference><Citation>Toure M., Crews C.M. Small-Molecule PROTACS: New Approaches to Protein Degradation. Angew. Chem. Int. Ed. Engl. 2016;55:1966–1973. doi: 10.1002/anie.201507978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201507978</ArticleId><ArticleId IdType="pubmed">26756721</ArticleId></ArticleIdList></Reference><Reference><Citation>Alugubelli Y.R., Xiao J., Khatua K., Kumar S., Sun L., Ma Y., Ma X.R., Vulupala V.R., Atla S., Blankenship L.R., et al. Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease. J. Med. Chem. 2024;67:6495–6507. doi: 10.1021/acs.jmedchem.3c02416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.3c02416</ArticleId><ArticleId IdType="pmc">PMC11056980</ArticleId><ArticleId IdType="pubmed">38608245</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifagni D., Lenci E., De Santis A., Orsetti A., Barracchia C.G., Tedesco F., Bellini Puglielli R., Lucarelli F., Lauriola A., Assfalg M., et al. Development of a GC-376 Based Peptidomimetic PROTAC as a Degrader of 3-Chymotrypsin-like Protease of SARS-CoV-2. ACS Med. Chem. Lett. 2024;15:250–257. doi: 10.1021/acsmedchemlett.3c00498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.3c00498</ArticleId><ArticleId IdType="pmc">PMC10860180</ArticleId><ArticleId IdType="pubmed">38352832</ArticleId></ArticleIdList></Reference><Reference><Citation>Desantis J., Bazzacco A., Eleuteri M., Tuci S., Bianconi E., Macchiarulo A., Mercorelli B., Loregian A., Goracci L. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity. Eur. J. Med. Chem. 2024;268:116202. doi: 10.1016/j.ejmech.2024.116202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2024.116202</ArticleId><ArticleId IdType="pubmed">38394929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang X., Wang J., Zhou J., Xu Y., An J., Warshel A., Huang Z. A Chemical Strategy for the Degradation of the Main Protease of SARS-CoV-2 in Cells. J. Am. Chem. Soc. 2023;145:27248–27253. doi: 10.1021/jacs.3c12678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.3c12678</ArticleId><ArticleId IdType="pubmed">38064654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C., Sacco M.D., Hurst B., Townsend J.A., Hu Y., Szeto T., Zhang X., Tarbet B., Marty M.T., Chen Y., et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020;30:678–692. doi: 10.1038/s41422-020-0356-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0356-z</ArticleId><ArticleId IdType="pmc">PMC7294525</ArticleId><ArticleId IdType="pubmed">32541865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Lovell S., Tiew K.C., Mandadapu S.R., Alliston K.R., Battaile K.P., Groutas W.C., Chang K.O. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol. 2012;86:11754–11762. doi: 10.1128/JVI.01348-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01348-12</ArticleId><ArticleId IdType="pmc">PMC3486288</ArticleId><ArticleId IdType="pubmed">22915796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito T. Protein degraders—From thalidomide to new PROTACs. J. Biochem. 2024;175:507–519. doi: 10.1093/jb/mvad113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jb/mvad113</ArticleId><ArticleId IdType="pubmed">38140952</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y.X., Braggio E., Shi C.X., Bruins L.A., Schmidt J.E., Van Wier S., Chang X.B., Bjorklund C.C., Fonseca R., Bergsagel P.L., et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771–4779. doi: 10.1182/blood-2011-05-356063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-05-356063</ArticleId><ArticleId IdType="pmc">PMC3208291</ArticleId><ArticleId IdType="pubmed">21860026</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi A.K., Kang J., Havens C.G., Conklin T., Ning Y., Wu L., Ito T., Ando H., Waldman M.F., Thakurta A., et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.) Br. J. Haematol. 2014;164:811–821. doi: 10.1111/bjh.12708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12708</ArticleId><ArticleId IdType="pmc">PMC4232904</ArticleId><ArticleId IdType="pubmed">24328678</ArticleId></ArticleIdList></Reference><Reference><Citation>Girardini M., Maniaci C., Hughes S.J., Testa A., Ciulli A. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs. Bioorg. Med. Chem. 2019;27:2466–2479. doi: 10.1016/j.bmc.2019.02.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2019.02.048</ArticleId><ArticleId IdType="pmc">PMC6561380</ArticleId><ArticleId IdType="pubmed">30826187</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehl C.J., Ciulli A. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders. Chem. Soc. Rev. 2022;51:8216–8257. doi: 10.1039/D2CS00387B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2CS00387B</ArticleId><ArticleId IdType="pmc">PMC9528729</ArticleId><ArticleId IdType="pubmed">35983982</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science. 2003;300:1763–1767. doi: 10.1126/science.1085658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1085658</ArticleId><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjomäki V., Kalander K., Hellman M., Permi P. Enteroviruses and coronaviruses: Similarities and therapeutic targets. Expert Opin. Ther. Targets. 2021;25:479–489. doi: 10.1080/14728222.2021.1952985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2021.1952985</ArticleId><ArticleId IdType="pmc">PMC8330013</ArticleId><ArticleId IdType="pubmed">34253126</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W., Qi Z., Wang J. The Function and Mechanism of Enterovirus 71 (EV71) 3C Protease. Curr. Microbiol. 2020;77:1968–1975. doi: 10.1007/s00284-020-02082-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-020-02082-4</ArticleId><ArticleId IdType="pubmed">32556480</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen O.H., Svedin E., Kapell S., Nurminen A., Hytönen V.P., Flodström-Tullberg M. Enteroviral proteases: Structure, host interactions and pathogenicity. Rev. Med. Virol. 2016;26:251–267. doi: 10.1002/rmv.1883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1883</ArticleId><ArticleId IdType="pmc">PMC7169145</ArticleId><ArticleId IdType="pubmed">27145174</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., George S., Kusov Y., Perbandt M., Anemüller S., Mesters J.R., Norder H., Coutard B., Lacroix C., Leyssen P., et al. 3C protease of enterovirus 68: Structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J. Virol. 2013;87:4339–4351. doi: 10.1128/JVI.01123-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01123-12</ArticleId><ArticleId IdType="pmc">PMC3624371</ArticleId><ArticleId IdType="pubmed">23388726</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikonov O.S., Chernykh E.S., Garber M.B., Nikonova E.Y. Enteroviruses: Classification, Diseases They Cause, and Approaches to Development of Antiviral Drugs. Biochem. Biokhimiia. 2017;82:1615–1631. doi: 10.1134/S0006297917130041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297917130041</ArticleId><ArticleId IdType="pmc">PMC7087576</ArticleId><ArticleId IdType="pubmed">29523062</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier R., Krebs P., Ludewig B. Immunopathological basis of virus-induced myocarditis. Clin. Dev. Immunol. 2004;11:1–5. doi: 10.1080/10446670410001670427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10446670410001670427</ArticleId><ArticleId IdType="pmc">PMC2275413</ArticleId><ArticleId IdType="pubmed">15154605</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauntt C., Huber S. Coxsackievirus experimental heart diseases. Front. Biosci. 2003;8:e23–e35. doi: 10.2741/928.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/928</ArticleId><ArticleId IdType="pubmed">12456330</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugo D., Krogstad P. Enteroviruses in the early 21st century: New manifestations and challenges. Curr. Opin. Pediatr. 2016;28:107–113. doi: 10.1097/MOP.0000000000000303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOP.0000000000000303</ArticleId><ArticleId IdType="pmc">PMC4750492</ArticleId><ArticleId IdType="pubmed">26709690</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan W., McDougal M.B., Schoggins J.W. Enterovirus 3C Protease Cleaves TRIM7 To Dampen Its Antiviral Activity. J. Virol. 2022;96:e0133222. doi: 10.1128/jvi.01332-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01332-22</ArticleId><ArticleId IdType="pmc">PMC9555159</ArticleId><ArticleId IdType="pubmed">36106874</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorbalenya A.E., Donchenko A.P., Blinov V.M., Koonin E.V. Cysteine proteases of positive strand RNA viruses and chymotrypsin-like serine proteases. A distinct protein superfamily with a common structural fold. FEBS Lett. 1989;243:103–114. doi: 10.1016/0014-5793(89)80109-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(89)80109-7</ArticleId><ArticleId IdType="pubmed">2645167</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan K., Wei P., Feng Q., Chen S., Huang C., Ma L., Lai B., Pei J., Liu Y., Chen J., et al. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J. Biol. Chem. 2004;279:1637–1642. doi: 10.1074/jbc.M310875200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M310875200</ArticleId><ArticleId IdType="pmc">PMC7980035</ArticleId><ArticleId IdType="pubmed">14561748</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lin D., Kusov Y., Nian Y., Ma Q., Wang J., von Brunn A., Leyssen P., Lanko K., Neyts J., et al. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment. J. Med. Chem. 2020;63:4562–4578. doi: 10.1021/acs.jmedchem.9b01828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b01828</ArticleId><ArticleId IdType="pubmed">32045235</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand K., Palm G.J., Mesters J.R., Siddell S.G., Ziebuhr J., Hilgenfeld R. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. Embo J. 2002;21:3213–3224. doi: 10.1093/emboj/cdf327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/cdf327</ArticleId><ArticleId IdType="pmc">PMC126080</ArticleId><ArticleId IdType="pubmed">12093723</ArticleId></ArticleIdList></Reference><Reference><Citation>Schechter I., Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967;27:157–162. doi: 10.1016/S0006-291X(67)80055-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(67)80055-X</ArticleId><ArticleId IdType="pubmed">6035483</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh E., Khan R.J., Jha R.K., Amera G.M., Jain M., Singh R.P., Muthukumaran J., Singh A.K. A comprehensive review on promising anti-viral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods. J. Genet. Eng. Biotechnol. 2020;18:69. doi: 10.1186/s43141-020-00085-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43141-020-00085-z</ArticleId><ArticleId IdType="pmc">PMC7607901</ArticleId><ArticleId IdType="pubmed">33141358</ArticleId></ArticleIdList></Reference><Reference><Citation>Azevedo P., Camargo P.G., Constant L.E.C., Costa S.D.S., Silva C.S., Rosa A.S., Souza D.D.C., Tucci A.R., Ferreira V.N.S., Oliveira T.K.F., et al. Statine-based peptidomimetic compounds as inhibitors for SARS-CoV-2 main protease (SARS-CoV-2 Mpro) Sci. Rep. 2024;14:8991. doi: 10.1038/s41598-024-59442-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-59442-4</ArticleId><ArticleId IdType="pmc">PMC11026380</ArticleId><ArticleId IdType="pubmed">38637583</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayek-Orduz Y., Vásquez A.F., Villegas-Torres M.F., Caicedo P.A., Achenie L.E.K., González Barrios A.F. Novel covalent and non-covalent complex-based pharmacophore models of SARS-CoV-2 main protease (M(pro)) elucidated by microsecond MD simulations. Sci. Rep. 2022;12:14030. doi: 10.1038/s41598-022-17204-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-17204-0</ArticleId><ArticleId IdType="pmc">PMC9386674</ArticleId><ArticleId IdType="pubmed">35982147</ArticleId></ArticleIdList></Reference><Reference><Citation>Fàbrega-Ferrer M., Herrera-Morandé A., Muriel-Goñi S., Pérez-Saavedra J., Bueno P., Castro V., Garaigorta U., Gastaminza P., Coll M. Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404. Antivir. Res. 2022;208:105458. doi: 10.1016/j.antiviral.2022.105458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105458</ArticleId><ArticleId IdType="pmc">PMC9632241</ArticleId><ArticleId IdType="pubmed">36336176</ArticleId></ArticleIdList></Reference><Reference><Citation>Göhl M., Zhang L., El Kilani H., Sun X., Zhang K., Brönstrup M., Hilgenfeld R. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease. Molecules. 2022;27:4292. doi: 10.3390/molecules27134292.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27134292</ArticleId><ArticleId IdType="pmc">PMC9268446</ArticleId><ArticleId IdType="pubmed">35807537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lockbaum G.J., Henes M., Lee J.M., Timm J., Nalivaika E.A., Thompson P.R., Kurt Yilmaz N., Schiffer C.A. Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode. Biochemistry. 2021;60:2925–2931. doi: 10.1021/acs.biochem.1c00414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.biochem.1c00414</ArticleId><ArticleId IdType="pmc">PMC8457326</ArticleId><ArticleId IdType="pubmed">34506130</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W., Jochmans D., Xie H., Yang H., Li J., Su H., Chang D., Wang J., Peng J., Zhu L., et al. Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2. J. Med. Chem. 2022;65:2794–2808. doi: 10.1021/acs.jmedchem.0c02258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c02258</ArticleId><ArticleId IdType="pubmed">33872498</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramajayam R., Tan K.P., Liu H.G., Liang P.H. Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors. Bioorg. Med. Chem. 2010;18:7849–7854. doi: 10.1016/j.bmc.2010.09.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2010.09.050</ArticleId><ArticleId IdType="pmc">PMC7127448</ArticleId><ArticleId IdType="pubmed">20947359</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramajayam R., Tan K.P., Liang P.H. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Biochem. Soc. Trans. 2011;39:1371–1375. doi: 10.1042/BST0391371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0391371</ArticleId><ArticleId IdType="pubmed">21936817</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandadapu S.R., Weerawarna P.M., Prior A.M., Uy R.A., Aravapalli S., Alliston K.R., Lushington G.H., Kim Y., Hua D.H., Chang K.O., et al. Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus. Bioorg. Med. Chem. Lett. 2013;23:3709–3712. doi: 10.1016/j.bmcl.2013.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2013.05.021</ArticleId><ArticleId IdType="pmc">PMC3750990</ArticleId><ArticleId IdType="pubmed">23727045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V., Shin J.S., Shie J.J., Ku K.B., Kim C., Go Y.Y., Huang K.F., Kim M., Liang P.H. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL(Pro) inhibitors. Antivir. Res. 2017;141:101–106. doi: 10.1016/j.antiviral.2017.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.02.007</ArticleId><ArticleId IdType="pmc">PMC7113684</ArticleId><ArticleId IdType="pubmed">28216367</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.C., Kuo C.J., Ko T.P., Hsu M.F., Tsui Y.C., Chang S.C., Yang S., Chen S.J., Chen H.C., Hsu M.C., et al. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds. J. Biol. Chem. 2009;284:7646–7655. doi: 10.1074/jbc.M807947200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M807947200</ArticleId><ArticleId IdType="pmc">PMC2658058</ArticleId><ArticleId IdType="pubmed">19144641</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo C.J., Liu H.G., Lo Y.K., Seong C.M., Lee K.I., Jung Y.S., Liang P.H. Individual and common inhibitors of coronavirus and picornavirus main proteases. FEBS Lett. 2009;583:549–555. doi: 10.1016/j.febslet.2008.12.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.12.059</ArticleId><ArticleId IdType="pmc">PMC7094298</ArticleId><ArticleId IdType="pubmed">19166843</ArticleId></ArticleIdList></Reference><Reference><Citation>Fili S., Valmas A., Christopoulou M., Spiliopoulou M., Nikolopoulos N., Lichière J., Logotheti S., Karavassili F., Rosmaraki E., Fitch A., et al. Coxsackievirus B3 protease 3C: Expression, purification, crystallization and preliminary structural insights. Acta Crystallogr. Sect. F Struct. Biol. Commun. 2016;72:877–884. doi: 10.1107/S2053230X16018513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S2053230X16018513</ArticleId><ArticleId IdType="pmc">PMC5137464</ArticleId><ArticleId IdType="pubmed">27917835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabsch W. XDS. Acta Crystallogr. D. Biol. Crystallogr. 2010;66:125–132. doi: 10.1107/S0907444909047337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909047337</ArticleId><ArticleId IdType="pmc">PMC2815665</ArticleId><ArticleId IdType="pubmed">20124692</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagin A.A., Teplyakov A. An approach to multi-copy search in molecular replacement. Acta Cryst. D. 2000;56:1622–1624. doi: 10.1107/S0907444900013780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444900013780</ArticleId><ArticleId IdType="pubmed">11092928</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams P.D., Afonine P.V., Bunkòczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.-W., Kapral G.J., Grosse-Kunstleve R.W., et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 2010;66:213–221. doi: 10.1107/S0907444909052925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909052925</ArticleId><ArticleId IdType="pmc">PMC2815670</ArticleId><ArticleId IdType="pubmed">20124702</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of Coot. Acta Cryst. D. 2010;66:486–501. doi: 10.1107/S0907444910007493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444910007493</ArticleId><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen V.B., Arendall W.B., III, Headd J.J., Keedy D.A., Immormino R.M., Kapral G.J., Murray L.W., Richardson J.S., Richardson D.C. MolProbity: All-atom structure validation for macromolecular crystallography. Acta Cryst. D. 2010;66:12–21. doi: 10.1107/S0907444909042073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444909042073</ArticleId><ArticleId IdType="pmc">PMC2803126</ArticleId><ArticleId IdType="pubmed">20057044</ArticleId></ArticleIdList></Reference><Reference><Citation>Grzesiek S., Bax A. Amino acid type determination in the sequential assignment procedure of uniformly 13C/15N-enriched proteins. J. Biomol. NMR. 1993;3:185–204. doi: 10.1007/BF00178261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00178261</ArticleId><ArticleId IdType="pubmed">8477186</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller R. The Computer Aided Resonance Assignment Tutorial. Cantina; Arth, Switzerland: 2004. pp. 1–81.</Citation></Reference><Reference><Citation>Williamson M.P. Using chemical shift perturbation to characterise ligand binding. Prog. Nucl. Magn. Reson. Spectrosc. 2013;73:1–16. doi: 10.1016/j.pnmrs.2013.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnmrs.2013.02.001</ArticleId><ArticleId IdType="pubmed">23962882</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrow N.A., Muhandiram R., Singer A.U., Pascal S.M., Kay C.M., Gish G., Shoelson S.E., Pawson T., Forman-Kay J.D., Kay L.E. Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation. Biochemistry. 1994;33:5984–6003. doi: 10.1021/bi00185a040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00185a040</ArticleId><ArticleId IdType="pubmed">7514039</ArticleId></ArticleIdList></Reference><Reference><Citation>Grzesiek S., Bax A. The Importance of Not Saturating H2o in Protein Nmr—Application to Sensitivity Enhancement and Noe Measurements. J. Am. Chem. Soc. 1993;115:12593–12594. doi: 10.1021/ja00079a052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja00079a052</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel M.A., Akke M., Palmer A.G., III Backbone dynamics of Escherichia coli ribonuclease HI: Correlations with structure and function in an active enzyme. J. Mol. Biol. 1995;246:144–163. doi: 10.1006/jmbi.1994.0073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.1994.0073</ArticleId><ArticleId IdType="pubmed">7531772</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia de la Torre J., Huertas M.L., Carrasco B. HYDRONMR: Prediction of NMR relaxation of globular proteins from atomic-level structures and hydrodynamic calculations. J. Magn. Reson. 2000;147:138–146. doi: 10.1006/jmre.2000.2170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmre.2000.2170</ArticleId><ArticleId IdType="pubmed">11042057</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews D.A., Dragovich P.S., Webber S.E., Fuhrman S.A., Patick A.K., Zalman L.S., Hendrickson T.F., Love R.A., Prins T.J., Marakovits J.T., et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. USA. 1999;96:11000–11007. doi: 10.1073/pnas.96.20.11000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.20.11000</ArticleId><ArticleId IdType="pmc">PMC34232</ArticleId><ArticleId IdType="pubmed">10500114</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson T.O., Hua Y., Luu H.T., Brown E.L., Chan F., Chu S.S., Dragovich P.S., Eastman B.W., Ferre R.A., Fuhrman S.A., et al. Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease. J. Med. Chem. 2002;45:2016–2023. doi: 10.1021/jm010435c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm010435c</ArticleId><ArticleId IdType="pubmed">11985469</ArticleId></ArticleIdList></Reference><Reference><Citation>Golovanov A.P., Hautbergue G.M., Wilson S.A., Lian L.Y. A simple method for improving protein solubility and long-term stability. J. Am. Chem. Soc. 2004;126:8933–8939. doi: 10.1021/ja049297h.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja049297h</ArticleId><ArticleId IdType="pubmed">15264823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo C.J., Shie J.J., Fang J.M., Yen G.R., Hsu J.T., Liu H.G., Tseng S.N., Chang S.C., Lee C.Y., Shih S.R., et al. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg. Med. Chem. 2008;16:7388–7398. doi: 10.1016/j.bmc.2008.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2008.06.015</ArticleId><ArticleId IdType="pmc">PMC7125518</ArticleId><ArticleId IdType="pubmed">18583140</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu L., Ye F., Feng Y., Yu F., Wang Q., Wu Y., Zhao C., Sun H., Huang B., Niu P., et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat. Commun. 2020;11:4417. doi: 10.1038/s41467-020-18233-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18233-x</ArticleId><ArticleId IdType="pmc">PMC7474075</ArticleId><ArticleId IdType="pubmed">32887884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C., Zhu Z., Jiang H., Zou X., Zeng X., Wang J., Zeng P., Li W., Zhou X., Zhang J., et al. Structural Basis for Coronaviral Main Proteases Inhibition by the 3CLpro Inhibitor GC376. J. Mol. Biol. 2024;436:168474. doi: 10.1016/j.jmb.2024.168474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2024.168474</ArticleId><ArticleId IdType="pubmed">38311236</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng S., Feng Y., Li W., Liu T., Lv X., Tong X., Xi G., Ye X., Li X. Development of novel antivrial agents that induce the degradation of the main protease of human-infecting coronaviruses. Eur. J. Med. Chem. 2024;275:116629. doi: 10.1016/j.ejmech.2024.116629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2024.116629</ArticleId><ArticleId IdType="pubmed">38941718</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>